SEC Form 4 · accession 0001209191-18-034866
Insight Molecular Diagnostics Inc. · IMDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William Annett
Officer — President and CEO · Director
Period of report
May 23, 2018
Accepted (ET)
Jun 1, 2018 · 7:41 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001642380
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF1 | $2.35 | May 23, 2018 | A | 180,000 | A | — | May 22, 2028 | Common Stock | 180,000 | 180,000 | D |
| Option to Purchase Common StockF2 | $4.70 | holding | — | — | — | — | Feb 16, 2027 | Common Stock | 225,000 | 250,000 | D |
| Option to Purchase Common StockF3 | $3.06 | holding | — | — | — | — | Feb 15, 2026 | Common Stock | 250,000 | 250,000 | D |
| Option to Purchase Common StockF4 | $2.20 | holding | — | — | — | — | Jun 15, 2025 | Common Stock | 605,000 | 605,000 | D |
| Option to Purchase Common StockF5 | $2.20 | holding | — | — | — | — | Jan 8, 2025 | Common Stock | 5,000 | 5,000 | D |
Explanation of responses
- F1One quarter of the options shall vest upon completion of the clinical utility study for OncoCyte's DetermaVu product candidate and OncoCyte has received a publication date for a full article describing those results, and the balance shall vest upon obtaining a Medicare local coverage determination for OncoCyte's DetermaVu product candidate.
- F2One quarter of the options vested on February 16, 2018, and the balance shall vest thereafter in 36 monthly installments upon the completion of each month of continuous employment.
- F3One quarter of the options vested on February 15, 2017, and the balance shall vest thereafter in 36 monthly installments upon the completion of each month of continuous employment.
- F4One quarter of the options vested on June 15, 2016, and the balance shall vest thereafter in 36 monthly installments upon the completion of each month of continuous employment.
- F5Became exercisable in two equal installments based upon continued service on the board of directors from the date of grant on January 9, 2015.